Recruitment, Infiltration, and Cytotoxicity of HLA-Independent Killer Lymphocytes in Three-Dimensional Melanoma Models.

3D models cell therapy imaging melanoma

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
11 May 2021
Historique:
received: 26 12 2020
revised: 28 04 2021
accepted: 05 05 2021
entrez: 2 6 2021
pubmed: 3 6 2021
medline: 3 6 2021
Statut: epublish

Résumé

Cancer adoptive cell therapy (ACT) with HLA-independent tumor killer lymphocytes is a promising approach, with intrinsic features potentially addressing crucial tumor-escape mechanisms of checkpoint inhibitors. Cytokine-induced Killer (CIK) and Natural Killer (NK) lymphocytes share similar tumor-killing mechanisms, with preclinical evidence of intense activity against multiple solid tumors and currently testing in clinical studies. To improve the effective clinical translation of such ACT approaches, several fundamental questions still need to be addressed within appropriate preclinical contexts, capable of overcoming limitations imposed by most traditional two-dimensional assays. Here, we developed a novel experimental approach to explore, dissect, and visualize the interactions of CIK and NK lymphocytes with melanoma tumors in vitro in 3D. Primary melanoma cells were assembled into small tumors that were dispersed in a 3D matrix and challenged with patient-derived CIK or the NK-92 cell line. By means of imaging-based methods, we reported, visualized, and quantitatively measured the recruitment of CIK and NK on the 3D targets, their infiltration, and cytotoxic activity. Our results support the effective tumor recruitment and tumor infiltration by CIK and NK. Such features appeared dependent on the specific geometric aspects of the environment but can be explained in terms of directional migration toward the tumor, without invoking major feedback components. Overall, our 3D platform allows us to monitor the processes of tumor recruitment, infiltration, and killing by means of live measurements, revealing important kinetic aspects of ACT with CIK and NK against melanoma.

Identifiants

pubmed: 34065007
pii: cancers13102302
doi: 10.3390/cancers13102302
pmc: PMC8151151
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : IG-2017 n. 20259
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : IG-23211
Organisme : FPRC ONLUS 5x1000, Ministero della Salute 2015
ID : Cancer ImGen
Organisme : Università degli Studi di Torino
ID : Fondo Ricerca Locale 2017
Organisme : Ministero della Salute
ID : Ricerca Corrente 2020
Organisme : Università degli Studi di Torino
ID : Fondo Ricerca Locale 2019 PULA_RILO_19_01
Organisme : Fondazione del Piemonte per l'Oncologia (FPO-IRCCS)
ID : Young Investigator Grant 2020

Références

Cell Death Dis. 2018 Mar 6;9(3):366
pubmed: 29511158
Oncoimmunology. 2018 Jan 10;7(4):e1417721
pubmed: 29632736
J Neurooncol. 2014 May;118(1):109-16
pubmed: 24532241
Semin Immunol. 2017 Jun;31:37-54
pubmed: 28838796
P T. 2017 Jun;42(6):375-383
pubmed: 28579724
Lab Invest. 2017 Jun;97(6):669-697
pubmed: 28346400
Neoplasia. 2015 Jan;17(1):1-15
pubmed: 25622895
Am J Cancer Res. 2019 May 01;9(5):945-958
pubmed: 31218103
J Clin Immunol. 2002 May;22(3):131-6
pubmed: 12078854
Self Nonself. 2011 Apr;2(2):80-84
pubmed: 22299059
J Cell Physiol. 2020 Dec;235(12):9291-9303
pubmed: 32484595
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Exp Mol Med. 2018 Dec 13;50(12):1-11
pubmed: 30546008
Clin Cancer Res. 2013 Aug 15;19(16):4347-58
pubmed: 23794732
J Transl Med. 2015 Aug 25;13:277
pubmed: 26303618
Nat Rev Drug Discov. 2015 Jul;14(7):487-98
pubmed: 26000725
Cytotherapy. 2013 Dec;15(12):1563-70
pubmed: 24094496
Curr Pharm Biotechnol. 2015;16(9):771-81
pubmed: 26087990
Oncoimmunology. 2018 Aug 6;7(11):e1465161
pubmed: 30393581
J Autoimmun. 2017 Dec;85:32-44
pubmed: 28679475
Clin Cancer Res. 2013 Jul 15;19(14):3977-86
pubmed: 23741070
Int J Mol Sci. 2018 Jan 25;19(2):
pubmed: 29370095
J Exp Clin Cancer Res. 2019 Mar 22;38(1):117
pubmed: 30898166
J Vis Exp. 2011 May 06;(51):
pubmed: 21587162
Cancer Immunol Immunother. 2019 May;68(5):773-785
pubmed: 30747243
PLoS One. 2012;7(8):e42522
pubmed: 22905142
Cancer J. 2017 Jan/Feb;23(1):48-53
pubmed: 28114254
Nat Rev Cancer. 2008 Apr;8(4):299-308
pubmed: 18354418
J Cancer. 2017 Feb 25;8(5):761-773
pubmed: 28382138
Curr Opin Immunol. 2018 Apr;51:55-61
pubmed: 29525346
Int J Mol Sci. 2019 Sep 03;20(17):
pubmed: 31484350
Nat Methods. 2019 Dec;16(12):1226-1232
pubmed: 31570887
Front Immunol. 2016 Mar 14;7:91
pubmed: 27014270
Br J Cancer. 1999 Nov;81(6):1009-16
pubmed: 10576658
Clin Cancer Res. 2010 Oct 1;16(19):4892-8
pubmed: 20719934
Immunotherapy. 2015;7(9):999-1010
pubmed: 26310715
Methods Mol Biol. 2020;2055:325-350
pubmed: 31502159
Adv Drug Deliv Rev. 2014 Dec 15;79-80:145-54
pubmed: 24819215
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
J Clin Invest. 2007 May;117(5):1204-12
pubmed: 17476350
Front Oncol. 2020 Jan 31;10:59
pubmed: 32083009
Nat Rev Cancer. 2018 Jul;18(7):407-418
pubmed: 29692415
Clin Cancer Res. 2015 Mar 15;21(6):1258-66
pubmed: 25770293
Blood. 2004 Apr 15;103(8):3065-72
pubmed: 15070686
Clin Cancer Res. 2017 May 1;23(9):2277-2288
pubmed: 27815354
Curr Opin Immunol. 2009 Apr;21(2):233-40
pubmed: 19304471
Biomaterials. 2020 Feb;232:119744
pubmed: 31918229
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
J Cancer Res Clin Oncol. 2011 Feb;137(2):305-10
pubmed: 20407789
Biotechnol Bioeng. 2019 Jan;116(1):206-226
pubmed: 30367820
Cancer Metastasis Rev. 2016 Dec;35(4):601-629
pubmed: 27858305
Am J Cancer Res. 2019 Feb 01;9(2):406-414
pubmed: 30906637
Semin Immunol. 2016 Feb;28(1):64-72
pubmed: 26611350
Front Immunol. 2018 Apr 23;9:857
pubmed: 29740450
Oncoimmunology. 2018 Nov 11;8(2):e1528411
pubmed: 30713783
Virchows Arch. 2019 Apr;474(4):449-461
pubmed: 30470934
Front Immunol. 2020 Dec 10;11:603640
pubmed: 33362787
Clin Cancer Res. 2020 Dec 1;26(23):6321-6334
pubmed: 32900797

Auteurs

Ilenia Iaia (I)

Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.
Department of Oncology, University of Turin, 10060 Candiolo, Italy.

Loretta Gammaitoni (L)

Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.

Giulia Cattaneo (G)

Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.
Department of Oncology, University of Turin, 10060 Candiolo, Italy.

Lidia Giraudo (L)

Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.

Chiara Donini (C)

Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.
Department of Oncology, University of Turin, 10060 Candiolo, Italy.

Erika Fiorino (E)

Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.
Department of Oncology, University of Turin, 10060 Candiolo, Italy.

Luca Primo (L)

Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.
Department of Oncology, University of Turin, 10060 Candiolo, Italy.

Fabrizio Carnevale-Schianca (F)

Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.

Massimo Aglietta (M)

Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.
Department of Oncology, University of Turin, 10060 Candiolo, Italy.

Alberto Puliafito (A)

Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.
Department of Oncology, University of Turin, 10060 Candiolo, Italy.

Dario Sangiolo (D)

Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.
Department of Oncology, University of Turin, 10060 Candiolo, Italy.

Classifications MeSH